Investors of Hims & Hers Health, Inc. Urged to Join Class Action Lawsuit by November 2, 2026
On October 14, 2026, Robbins Geller Rudman & Dowd LLP announced an opportunity for investors who purchased or acquired Hims & Hers Health, Inc. (NYSE: HIMS) securities between August 4, 2025, and July 29, 2026, inclusive, to seek appointment as lead plaintiff in a class action lawsuit against the company. The deadline for this application is November 2, 2026. This lawsuit is significant, as it aims to address serious allegations related to the company's business practices. These allegations include violations of the Securities Exchange Act of 1934 by Hims & Hers and certain executives, who are accused of making misleading statements and failing to disclose crucial information regarding their practices.
The claims detail that the company allegedly shared consumers' health information with third-party advertising platforms and charged users for prescriptions right after they submitted an intake form, contrary to the promise of consulting a medical provider first. This generates significant concern about customer privacy and the ethics of their billing practices. Regulatory scrutiny ensued, placing Hims & Hers under the microscope of the Federal Trade Commission (FTC), which filed a lawsuit against the telehealth provider for deceptive practices and privacy violations.
According to the class action lawsuit, as shared by the FTC, Hims & Hers is accused of misleading customers regarding their privacy policies and billing practices. Specifically, the lawsuit mentions that Hims & Hers charged users almost immediately after they submitted prescription requests, which contradicts the company’s assurances about consulting medical professionals. The culmination of these events led to a notable 15% drop in Hims & Hers stock prices following the FTC's announcement of its lawsuit.
For investors who have suffered substantial losses due to these practices, this class action presents an opportunity to partake in potential recovery efforts. Being appointed as a lead plaintiff means representing the interests of all class members, with the ability to choose a law firm for the litigation, although participation does not restrict potential recoveries for those who do not assume this role.
As one of the leading firms in securities fraud and shareholder rights litigation, Robbins Geller has previously secured significant settlements for clients, including over $916 million in 2025 alone. The firm has established a reputation for fighting for investor rights, recovering $8.4 billion in the past five years and being recognized as the premier choice for securities class action litigation.
If you are an investor of Hims & Hers Health, Inc. and believe you have accrued losses due to the alleged misleading tactics of the company, Robbins Geller encourages you to take action by reaching out for more information or to initiate your application to join the lawsuit. The firm can be contacted directly to get involved in this matter, ensuring that investor voices are heard and represented in this significant class action that aims to hold Hims & Hers accountable for its actions.
For those seeking further information, visit Robbins Geller's website or contact the attorneys directly at 800-851-7783 or email at [email protected].
The claims detail that the company allegedly shared consumers' health information with third-party advertising platforms and charged users for prescriptions right after they submitted an intake form, contrary to the promise of consulting a medical provider first. This generates significant concern about customer privacy and the ethics of their billing practices. Regulatory scrutiny ensued, placing Hims & Hers under the microscope of the Federal Trade Commission (FTC), which filed a lawsuit against the telehealth provider for deceptive practices and privacy violations.
According to the class action lawsuit, as shared by the FTC, Hims & Hers is accused of misleading customers regarding their privacy policies and billing practices. Specifically, the lawsuit mentions that Hims & Hers charged users almost immediately after they submitted prescription requests, which contradicts the company’s assurances about consulting medical professionals. The culmination of these events led to a notable 15% drop in Hims & Hers stock prices following the FTC's announcement of its lawsuit.
For investors who have suffered substantial losses due to these practices, this class action presents an opportunity to partake in potential recovery efforts. Being appointed as a lead plaintiff means representing the interests of all class members, with the ability to choose a law firm for the litigation, although participation does not restrict potential recoveries for those who do not assume this role.
As one of the leading firms in securities fraud and shareholder rights litigation, Robbins Geller has previously secured significant settlements for clients, including over $916 million in 2025 alone. The firm has established a reputation for fighting for investor rights, recovering $8.4 billion in the past five years and being recognized as the premier choice for securities class action litigation.
If you are an investor of Hims & Hers Health, Inc. and believe you have accrued losses due to the alleged misleading tactics of the company, Robbins Geller encourages you to take action by reaching out for more information or to initiate your application to join the lawsuit. The firm can be contacted directly to get involved in this matter, ensuring that investor voices are heard and represented in this significant class action that aims to hold Hims & Hers accountable for its actions.
For those seeking further information, visit Robbins Geller's website or contact the attorneys directly at 800-851-7783 or email at [email protected].
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.